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Blood culture 240 31
Respiratory 126 2
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With the recent publication of the MERTH study [1],
ethoprim/sulfamethoxazole (SXT) monotherapy will be used
reasingly in the treatment of melioidosis during the eradication
se, and possibly as the only treatment for some mild infections.
 therefore important to know the prevalence of SXT resistance
urkholderia pseudomallei. This is difﬁcult to test in vitro, with
 diffusion testing overestimating resistance, and indistinct end-
nts in all methods [2]. Even using the Etest method to estimate
 minimum inhibitory concentration (MIC), SXT resistance rates
high as 24% in a year have occasionally been reported from
iland [3]. Recent data from Northern Australia published in this
rnal [4] are consistent with our own experience in Southeast
Fig.
min
doma and suggest that true resistance to SXT in B. pseudomallei is
ually very rare.
As our own experience indicated a substantially lower preva-
ce of SXT resistance than the literature suggests, we reviewed
tine data from our diagnostic laboratories in Laos (February
3 to October 2012) and Cambodia (February 2006 to December
2). Etest (bioMérieux, Basingstoke, UK) was performed accord-
 to the manufacturer’s instructions on all isolates in Vientiane
os) and on all isolates that appeared non-susceptible by disc dif-
ion testing [Clinical and Laboratory Standards Institute (CLSI)
2-A11 method; zone diameter < 16 mm]  in Siem Reap (Cambo-
), as previously recommended [3]. The sources of the strains
ted are shown in Table 1.
Of 769 sequential isolates, 99.2% (615/620) from Laos and 100%
9/149) from Cambodia were classiﬁed as susceptible to SXT
ording to CLSI criteria (trimethoprim MIC  ≤ 2 mg/L). Three iso-
s had a trimethoprim MIC  of 3 mg/L and two isolates had a
ethoprim MIC  of 4 mg/L. The range of MICs is shown in Fig. 1. 1. Distribution of trimethoprim/sulfamethoxazole (co-trimoxazole) Etest
imum inhibitory concentrations (MICs) of clinical isolates of Burkholderia pseu-
allei from (a) Laos and (b) Cambodia.
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of new species capable of producing this enzyme is of great con-
cern. KPC production is currently the main mechanism of resistance
to carbapenems in Enterobacteriaceae strains [1]. In Brazil, reports
of new species carrying the blaKPC gene have been made in differ-
ent regions [2]. However, there are rare reports of KPC-producing
Enterobacter gergoviae strains; as far as we are aware, there are only
two reports, both in the USA [3,4].
During routine bacteriological diagnosis in a public teaching
hospital in Recife (Brazil), a bacterial isolate identiﬁed as Enterobac-
ter spp. (named EG2) was  selected. This isolate was derived from
blood of a patient hospitalised in the intensive care unit (ICU). The
patient was  hospitalised in February 2008 with hepatic failure. Dur-
ing their hospital stay, the patient received piperacillin/tazobactam
(TZP) [500 mg  every 6 h (q6 h)] empirically for 2 days. After that,
therapy was changed to imipenem (250 mg  q6 h). Ten days later
the patient died. On the same day, blood samples showed a
carbapenem-resistant Enterobacter spp. isolate. Conﬁrmation of the
isolate identity by 16S ribosomal DNA sequencing revealed an E.
gergoviae isolate. This isolate was used for further analyses.
Minimum inhibitory concentrations (MICs) were determined by
broth microdilution according to Clinical and Laboratory Standards
Institute (CLSI) 2013 guidelines (M100-S23). Molecular analyses
were performed through sequencing after speciﬁc PCR for blaKPC,
for the most common -lactamase genes (blaCTX-M, blaTEM and
blaSHV) and the class 1 integron variable region. Furthermore, the
genetic environment of the blaKPC-2 gene was  analysed by speciﬁc
PCR for the region between ISKpn7  and blaKPC, according to Cuzon
et al. [1].
Plasmid DNA was obtained by a standard protocol and
was used to transform Escherichia coli DH5 chemocompetent
cells. Transformant cells were selected on Mueller–Hinton agar
containing 2 g/mL imipenem and 50 g/mL ticarcillin. Plasmid
typing was  performed by PCR-based replicon typing (PBRT) as pre-
viously described by Carattoli et al. [5].
Results of susceptibility assays showed that isolate EG2 was
multidrug-resistant (Table 1). Isolate EG2 harboured the blaKPC-2,
blaCTX-M-15, blaSHV-5 and blaTEM-1 genes (Table 1). Moreover, the
dfrA22 gene, which confers resistance to trimethoprim, was present
in the variable region of a class 1 integron. Plasmid analysis showedLetters to the Editor / International Jo
This conﬁrms that primary resistance of B. pseudomallei to S
is extremely uncommon and should rarely be a contraindicati
to SXT monotherapy. These results from Vientiane and Siem Re
closely mirror those of Crowe et al. in Darwin [4]. Although t
CLSI currently only recommends broth microdilution testing for
pseudomallei [5], many years of experience in melioidosis-endem
areas suggests that disc diffusion testing is reliable for all agen
except SXT, for which Etest gives acceptable results. We  think th
the misleading data in the literature are due to the difﬁculty
interpreting endpoints in testing susceptibility of B. pseudomallei
SXT. We  tried to follow the manufacturer’s instructions and read t
Etest at 80% inhibition, but this is a somewhat subjective endpoi
However, the really important thing that remains to be establish
is whether SXT MICs can predict the outcome of SXT monothera
in melioidosis.
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Carbapenem-resistant Enterobacter gergoviae
harbouring blaKPC-2 in Brazil
Sir,
Worldwide, Klebsiella pneumoniae carbapenemase (KPC) dete
tion has been extensively reported every year, and the detectithat EG2 had 133, 65, 25 and 2 kb plasmids. The presence of blaKPC-2,
blaCTX-M-15 and blaSHV-5 genes was conﬁrmed by PCR in transfor-
mant recipient cells, named T-EG2. Analysis of the plasmid proﬁle
from donor and recipient cells showed that they shared only a
